SHR-A1921 + adebrelimab + carboplatin

**SHR-A1921 + adebrelimab + carboplatin** is a combination regimen comprised of three distinct agents: SHR-A1921 (an antibody-drug conjugate), adebrelimab (a fully humanized anti-PD-L1 immunotherapy monoclonal antibody), and carboplatin (a platinum-based cytotoxic chemotherapeutic). SHR-A1921 is being developed for the treatment of advanced solid tumors, particularly those that are platinum-resistant, such as recurrent epithelial ovarian cancer[1][3][7]. Adebrelimab blocks PD-L1 and enhances T-cell mediated antitumor immunity, approved and under clinical development primarily for small cell lung cancer in combination with platinum-based agents[2][6]. Carboplatin forms DNA crosslinks inducing apoptosis in rapidly dividing cells, commonly used as a backbone in many solid tumor cancer treatments. Together, this combination leverages targeted cytotoxicity (SHR-A1921), immune checkpoint blockade (adebrelimab), and DNA damage (carboplatin) as a multi-modal approach to increase antitumor efficacy, especially in settings where conventional platinum agents alone are insufficient.